+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Respiratory Disease Vaccine Market Research Report by Infection, by Type, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 5012997
  • Report
  • July 2021
  • Region: Global
  • 185 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Respiratory Disease Vaccine Market will Grow to USD 27.75 Billion by 2026, at a CAGR of 5.67%

FEATURED COMPANIES

  • AstraZeneca
  • Bavarian Nordic
  • Bayer AG
  • Bio Farma
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • MORE
The Global Respiratory Disease Vaccine Market size was estimated at USD 19.92 Billion in 2020 and expected to reach USD 20.98 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 5.67% to reach USD 27.75 Billion by 2026.



Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Respiratory Disease Vaccine to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Infection, the Respiratory Disease Vaccine Market was examined across Influenza Virus, Pertussis, Streptococcus Pneumoniae, and Tuberculosis.
  • Based on Age Group, the Respiratory Disease Vaccine Market was examined across Adolescent Vaccination, Adult Vaccination, and Infant Vaccination.
  • Based on Type, the Respiratory Disease Vaccine Market was examined across Bacterial Vaccine, Combination Vaccine, and Viral Vaccine.
  • Based on Geography, the Respiratory Disease Vaccine Market was examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas was further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific was further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa was further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. This ongoing research amplifies this research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Respiratory Disease Vaccine Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Respiratory Disease Vaccine Market, including AstraZeneca, Bavarian Nordic, Bayer AG, Bio Farma, Dynavax Technologies Corporation, Emergent BioSolutions, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Seqirus USA Inc., and Serum institute of India Private Limited.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Respiratory Disease Vaccine Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Respiratory Disease Vaccine Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Respiratory Disease Vaccine Market?
4. What is the competitive strategic window for opportunities in the Global Respiratory Disease Vaccine Market?
5. What are the technology trends and regulatory frameworks in the Global Respiratory Disease Vaccine Market?
6. What is the market share of the leading vendors in the Global Respiratory Disease Vaccine Market?
7. What modes and strategic moves are considered suitable for entering the Global Respiratory Disease Vaccine Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca
  • Bavarian Nordic
  • Bayer AG
  • Bio Farma
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Infection Outlook
3.4. Age Group Outlook
3.5. Type Outlook
3.6. Geography Outlook
3.7. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of respiratory disorders
5.1.1.2. Clinical trials and vaccines developments in pipeline
5.1.1.3. Government initiatives supporting respiratory health
5.1.2. Restraints
5.1.2.1. Lack of inadequate delivery infrastructure & limited awareness
5.1.3. Opportunities
5.1.3.1. Increasing R&D expenditure by leading companies
5.1.3.2. Increase vaccine availability through reselling collaborations
5.1.4. Challenges
5.1.4.1. Consumer trust & confidence in respiratory disease vaccination
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Respiratory Disease Vaccine Market, by Infection
6.1. Introduction
6.2. Influenza Virus
6.3. Pertussis
6.4. Streptococcus Pneumoniae
6.5. Tuberculosis

7. Respiratory Disease Vaccine Market, by Age Group
7.1. Introduction
7.2. Adolescent Vaccination
7.3. Adult Vaccination
7.4. Infant Vaccination

8. Respiratory Disease Vaccine Market, by Type
8.1. Introduction
8.2. Bacterial Vaccine
8.3. Combination Vaccine
8.4. Viral Vaccine

9. Americas Respiratory Disease Vaccine Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Respiratory Disease Vaccine Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Thailand

11. Europe, Middle East & Africa Respiratory Disease Vaccine Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. AstraZeneca
13.2. Bavarian Nordic
13.3. Bayer AG
13.4. Bio Farma
13.5. Dynavax Technologies Corporation
13.6. Emergent BioSolutions, Inc.
13.7. GlaxoSmithKline plc
13.8. Merck & Co., Inc.
13.9. Pfizer Inc.
13.10. Sanofi S.A.
13.11. Seqirus USA Inc.
13.12. Serum institute of India Private Limited

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2020 VS 2026 (USD BILLION)
FIGURE 2. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2020 (USD BILLION)
FIGURE 3. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2020 (USD BILLION)
FIGURE 4. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2020 (USD BILLION)
FIGURE 5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2020 (USD BILLION)
FIGURE 6. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: MARKET DYNAMICS
FIGURE 8. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 9. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2020 VS 2026 (%)
FIGURE 10. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2020 VS 2026 (USD BILLION)
FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2026
FIGURE 12. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFLUENZA VIRUS, 2018-2026 (USD BILLION)
FIGURE 13. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFLUENZA VIRUS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 14. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PERTUSSIS, 2018-2026 (USD BILLION)
FIGURE 15. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PERTUSSIS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 16. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIAE, 2018-2026 (USD BILLION)
FIGURE 17. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIAE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 18. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS, 2018-2026 (USD BILLION)
FIGURE 19. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 20. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2020 VS 2026 (%)
FIGURE 21. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2020 VS 2026 (USD BILLION)
FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2026
FIGURE 23. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, 2018-2026 (USD BILLION)
FIGURE 24. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 25. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT VACCINATION, 2018-2026 (USD BILLION)
FIGURE 26. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT VACCINATION, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 27. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT VACCINATION, 2018-2026 (USD BILLION)
FIGURE 28. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT VACCINATION, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 29. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
FIGURE 30. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2020 VS 2026 (USD BILLION)
FIGURE 31. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2026
FIGURE 32. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY BACTERIAL VACCINE, 2018-2026 (USD BILLION)
FIGURE 33. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY BACTERIAL VACCINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 34. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COMBINATION VACCINE, 2018-2026 (USD BILLION)
FIGURE 35. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COMBINATION VACCINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 36. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VACCINE, 2018-2026 (USD BILLION)
FIGURE 37. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VACCINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 38. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 39. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 40. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 41. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 42. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 43. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 44. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 45. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 46. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 47. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 48. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 49. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 50. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 51. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 52. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 53. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 54. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 55. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 56. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 57. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 58. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 59. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 60. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 61. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 62. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 63. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 64. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 65. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 66. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 67. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 68. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 69. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 70. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 71. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 72. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 73. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: FPNV POSITIONING MATRIX
FIGURE 74. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 75. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL RESPIRATORY DISEASE VACCINE MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 4. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFLUENZA VIRUS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 6. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PERTUSSIS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIAE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 8. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 9. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 10. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 11. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT VACCINATION, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 12. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT VACCINATION, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 13. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 14. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY BACTERIAL VACCINE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 15. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COMBINATION VACCINE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 16. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VACCINE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 17. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 18. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 19. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 20. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 21. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 22. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 23. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 24. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 25. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 26. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 27. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 28. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 29. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 30. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 31. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 32. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 33. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 34. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 35. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 36. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 37. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 38. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 39. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 40. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 41. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 42. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 43. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 44. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 45. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 46. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 47. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 48. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 49. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 50. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 51. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 52. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 53. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 54. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 55. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 56. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 57. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 58. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 59. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 60. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 61. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 62. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 63. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 64. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 65. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 66. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 67. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 68. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 69. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 70. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 75. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 76. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 77. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 78. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 79. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 80. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 81. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 82. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 83. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 84. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 85. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 86. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 87. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 88. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 89. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 90. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 91. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 92. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 93. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 94. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 95. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 96. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 97. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 98. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 99. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 100. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 101. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 102. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 103. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 104. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 105. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2026 (USD BILLION)
TABLE 106. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2026 (USD BILLION)
TABLE 107. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 108. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: SCORES
TABLE 109. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: BUSINESS STRATEGY
TABLE 110. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: PRODUCT SATISFACTION
TABLE 111. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: RANKING
TABLE 112. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 113. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: MERGER & ACQUISITION
TABLE 114. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 115. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 116. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: INVESTMENT & FUNDING
TABLE 117. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 118. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • AstraZeneca
  • Bavarian Nordic
  • Bayer AG
  • Bio Farma
  • Dynavax Technologies Corporation
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Seqirus USA Inc.
  • Serum institute of India Private Limited
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll